Literature DB >> 2860771

The possible role of the ancillary properties of beta adrenoceptor antagonists in the management of angina pectoris.

J D Fitzgerald.   

Abstract

Beta adrenoceptor antagonists are effective in the symptomatic management of angina pectoris. This paper examines critically the possible influence of the ancillary properties of beta 1 selectivity, partial agonism and membrane-stabilizing action on the response in anginal patients. The response is categorized according to experimental, pharmacological and clinical endpoints, placing emphasis on the possible errors which may arise from extrapolation from the former to the latter. It is concluded: That selective beta adrenoceptor antagonism confers limited, but tangible advantages over non-selective antagonists in regard to patients with reversible airways obstruction, and also in the metabolic and haemodynamic response to acute hypoglycaemia. Cardioselectivity does not influence the central haemodynamic response to exercise, but lessens adrenaline-mediated hypertensive responses to smoking and hypoglycaemia. Non-selective partial agonists cause less reduction in resting ventricular function, but their effects on cardiac output during exercise are indistinguishable from full antagonists. Membrane stabilizing properties have a marked influence on the tolerability of these agents in terms of unwanted, nonspecific central nervous system symptoms. Unresolved questions relate to the influence of partial agonism on fatigue, metabolic responses, especially blood lipids and glucose, and the possibility of lesser efficacy in angina compared to full antagonists.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2860771     DOI: 10.1111/j.0954-6820.1985.tb08809.x

Source DB:  PubMed          Journal:  Acta Med Scand Suppl        ISSN: 0365-463X


  1 in total

1.  An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man.

Authors:  P M McCaffrey; J G Riddell; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.